Intraoperative electron radiotherapy in early invasive ductal breast cancer: 6-year median follow-up results of a prospective monocentric registry.
Accelerated partial breast irradiation (APBI)
Early stage breast cancer
Intraoperative electron radiotherapy (IOERT)
Journal
Breast cancer research : BCR
ISSN: 1465-542X
Titre abrégé: Breast Cancer Res
Pays: England
ID NLM: 100927353
Informations de publication
Date de publication:
23 11 2022
23 11 2022
Historique:
received:
28
09
2022
accepted:
17
11
2022
entrez:
24
11
2022
pubmed:
25
11
2022
medline:
26
11
2022
Statut:
epublish
Résumé
Intraoperative electron radiotherapy (IOERT) can be used to treat early breast cancer during the conservative surgery thus enabling shorter overall treatment times and reduced irradiation of organs at risk. We report on our first 996 patients enrolled prospectively in a registry trial. At Jules Bordet Institute, from February 2010 onwards, patients underwent partial IOERT of the breast. Women with unifocal invasive ductal carcinoma, aged 40 years or older, with a clinical tumour size ≤ 20 mm and tumour-free sentinel lymph node (on frozen section and immunohistochemical analysis). A 21 Gy dose was prescribed on the 90% isodose line in the tumour bed with the energy of 6 to 12 MeV (Mobetron®-IntraOp Medical). Thirty-seven ipsilateral tumour relapses occurred. Sixteen of those were in the same breast quadrant. Sixty patients died, and among those, 12 deaths were due to breast cancer. With 71.9 months of median follow-up, the 5-year Kaplan-Meier estimate of local recurrence was 2.7%. The rate of breast cancer local recurrence after IOERT is low and comparable to published results for IORT and APBI. IOERT is highly operator-dependent, and appropriate applicator sizing according to tumour size is critical. When used in a selected patient population, IOERT achieves a good balance between tumour control and late radiotherapy-mediated toxicity morbidity and mortality thanks to insignificant irradiation of organs at risk.
Sections du résumé
BACKGROUND
Intraoperative electron radiotherapy (IOERT) can be used to treat early breast cancer during the conservative surgery thus enabling shorter overall treatment times and reduced irradiation of organs at risk. We report on our first 996 patients enrolled prospectively in a registry trial.
METHODS
At Jules Bordet Institute, from February 2010 onwards, patients underwent partial IOERT of the breast. Women with unifocal invasive ductal carcinoma, aged 40 years or older, with a clinical tumour size ≤ 20 mm and tumour-free sentinel lymph node (on frozen section and immunohistochemical analysis). A 21 Gy dose was prescribed on the 90% isodose line in the tumour bed with the energy of 6 to 12 MeV (Mobetron®-IntraOp Medical).
RESULTS
Thirty-seven ipsilateral tumour relapses occurred. Sixteen of those were in the same breast quadrant. Sixty patients died, and among those, 12 deaths were due to breast cancer. With 71.9 months of median follow-up, the 5-year Kaplan-Meier estimate of local recurrence was 2.7%.
CONCLUSIONS
The rate of breast cancer local recurrence after IOERT is low and comparable to published results for IORT and APBI. IOERT is highly operator-dependent, and appropriate applicator sizing according to tumour size is critical. When used in a selected patient population, IOERT achieves a good balance between tumour control and late radiotherapy-mediated toxicity morbidity and mortality thanks to insignificant irradiation of organs at risk.
Identifiants
pubmed: 36419161
doi: 10.1186/s13058-022-01582-4
pii: 10.1186/s13058-022-01582-4
pmc: PMC9685863
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
83Informations de copyright
© 2022. The Author(s).
Références
N Engl J Med. 1993 Jun 3;328(22):1587-91
pubmed: 8387637
J Natl Compr Canc Netw. 2010 May;8(5):562-94
pubmed: 20495085
Lancet. 2019 Dec 14;394(10215):2165-2172
pubmed: 31813635
J Natl Compr Canc Netw. 2022 Jun;20(6):691-722
pubmed: 35714673
Breast Cancer Res Treat. 2020 Jul;182(1):229-238
pubmed: 32441019
N Engl J Med. 2010 Feb 11;362(6):513-20
pubmed: 20147717
J Clin Oncol. 2013 Jul 1;31(19):2382-7
pubmed: 23690420
Radiother Oncol. 2017 Apr;123(1):1-9
pubmed: 28391871
Cochrane Database Syst Rev. 2019 Sep 26;9:CD005360
pubmed: 31557310
Lancet. 2014 Feb 15;383(9917):603-13
pubmed: 24224997
Lancet. 2002 Apr 13;359(9314):1309-10
pubmed: 11965278
Semin Radiat Oncol. 2003 Jul;13(3):176-81
pubmed: 12903007
Lancet. 2017 Sep 9;390(10099):1048-1060
pubmed: 28779963
Front Oncol. 2021 Mar 11;11:617439
pubmed: 33777758
Lancet Oncol. 2021 May;22(5):597-608
pubmed: 33845035
Radiat Oncol. 2017 Jan 27;12(1):37
pubmed: 28193241
Surgery. 2006 Sep;140(3):467-71
pubmed: 16934611
Lancet. 2011 Nov 12;378(9804):1707-16
pubmed: 22019144
Ann Oncol. 2015 Sep;26 Suppl 5:v8-30
pubmed: 26314782
Radiother Oncol. 2013 Jan;106(1):21-7
pubmed: 23218711
Lancet. 2016 Jan 16;387(10015):229-38
pubmed: 26494415
Lancet Oncol. 2017 Feb;18(2):259-268
pubmed: 28094198
Eur J Cancer. 2015 Mar;51(4):451-463
pubmed: 25605582
Radiat Environ Biophys. 2021 Aug;60(3):459-474
pubmed: 34275005
Radiother Oncol. 2013 Aug;108(2):197-202
pubmed: 23742961
Lancet Oncol. 2022 Jan;23(1):e21-e31
pubmed: 34973228
Ann Oncol. 2013 Sep;24(9):2206-23
pubmed: 23917950
Lancet. 2020 May 23;395(10237):1613-1626
pubmed: 32580883
Radiother Oncol. 2016 Jul;120(1):119-23
pubmed: 27422584
Cancer Med. 2013 Oct;2(5):712-7
pubmed: 24403236
Breast J. 2003 Mar-Apr;9(2):106-12
pubmed: 12603383
Lancet Oncol. 2015 Mar;16(3):266-73
pubmed: 25637340
Medicina (Kaunas). 2019 Aug 21;55(9):
pubmed: 31438594
Lancet. 2019 Dec 14;394(10215):2155-2164
pubmed: 31813636
Indian J Cancer. 2018 Apr-Jun;55(2):166-169
pubmed: 30604730
J Clin Oncol. 2017 May 20;35(15):1641-1649
pubmed: 28319436
Breast Cancer Res Treat. 2019 Jun;175(3):531-545
pubmed: 30929116
Int J Breast Cancer. 2014;2014:627352
pubmed: 25009747
J Clin Oncol. 1990 Jan;8(1):113-8
pubmed: 2153190
Lancet. 2005 Dec 17;366(9503):2087-106
pubmed: 16360786
Ann Oncol. 2015 May;26(5):873-879
pubmed: 25725046
J Clin Oncol. 2020 Dec 10;38(35):4175-4183
pubmed: 32840419
Strahlenther Onkol. 2020 Sep;196(9):749-763
pubmed: 32350554
Br J Cancer. 2021 Aug;125(3):380-389
pubmed: 34035435
Cancer. 2001 Feb 15;91(4):647-59
pubmed: 11241230
Lancet Oncol. 2013 Dec;14(13):1269-77
pubmed: 24225155
Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2):259-265
pubmed: 27478165
Lancet. 1996 Sep 14;348(9029):708-13
pubmed: 8806289
Health Technol Assess. 2016 Sep;20(73):1-188
pubmed: 27689969
Pract Radiat Oncol. 2017 Mar - Apr;7(2):73-79
pubmed: 27866865
BMJ. 2020 Aug 19;370:m2836
pubmed: 32816842
Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1049-91
pubmed: 7713776